Country for PR: United Kingdom
Contributor: PR Newswire Europe
Thursday, July 30 2020 - 09:01
Trobix Bio completed Series A funding by a leading Japanese/Singapore fund
NETANYA, Israel, July 30, 2020, /PRNewswire-AsiaNet/--

Trobix Innovation Ltd. (Trobix Bio [ ]), an 
Israeli-based biotechnology company developing therapies to remove the threat 
of antimicrobial resistance, announces the closing of a US $ 3 Million Series A 
funding from its lead investor, Chartered Opus [ 
]. The funding will be used to advance the company's antimicrobial resistance 
platform technology and to further the pre-clinical development of the its lead 
product, TBX101.

"I am grateful to Chartered Opus for their confidence in our technology and 
their trust in our team", said Dr. Adi Elkeles, Founder & CEO of Trobix Bio. 
"Antimicrobial resistant threatens to undermine the achievements of modern 
medicine, and Trobix Bio is committed to developing products that can 
effectively tackle this imminent threat", he added.

"The Covid-19 pandemic stresses the urgent need to tackle the global challenges 
of infectious diseases, and the global need for a solution to the threat of 
antimicrobial resistance was there from day one", says Eyal Agmoni, Chairman of 
Chartered Group. "Trobix Bio is set to revolutionize the landscape of 
phage-based nanomedicine by introducing its game-changing, precision particle 
disruptive technology. We are very happy with the progress made by the team and 
are glad to be part of this unique venture". 

About Trobix Bio

Trobix Bio is a preclinical biotechnology company, developing therapies to 
remove the threat of antimicrobial resistance, a global crisis strongly 
evidenced nowadays during the COVID-19 Pandemic. Trobix Bio leverages its 
ActiSense™ and GoTrap™ technologies to develop phage-based products that can 
effectively deliver DNA to a wide range of bacterial pathogens, and actively 
sensitize these pathogens to antibiotics. The company's lead product, TBX101, 
aims to treat patients carrying gut antimicrobial resistant bacteria, resulting 
in an antibiotic sensitive gut microbiome. Trobix Bio's precision medicine 
technology minimizes resistance development to TBX101.

About Chartered Opus

Chartered Opus is a production platform for investment products combining 
structural and technological innovations to a new methodology in Structured 
Products. Opus is the preferred investment vehicle for the Chartered Group 
[ ] High-Tech division. In the past two years, 
Chartered group grew its high-tech portfolio to about 30 companies all with 
disruptive technologies, including being the anchor investor for TAU Ventures 
at Tel Aviv University.   

Logo - 

For more information, please contact:  
Dr. Adi Elkeles
CEO & co-Founder  
Trobix Bio

SOURCE: Trobix Innovation Ltd